The estimated Net Worth of Diane Hendricks is at least $1.13 Million dollars as of 18 December 2019. Diane Hendricks owns over 468,750 units of Monopar Therapeutics Inc stock worth over $1,125,000 and over the last 5 years Diane sold MNPR stock worth over $0.
Sign up
Diane Hendricks MNPR stock SEC Form 4 insiders trading
Diane has made over 1 trades of the Monopar Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Diane bought 468,750 units of MNPR stock worth $3,750,000 on 18 December 2019.
The largest trade Diane's ever made was buying 468,750 units of Monopar Therapeutics Inc stock on 18 December 2019 worth over $3,750,000. On average, Diane trades about 468,750 units every 0 days since 2019. As of 18 December 2019 Diane still owns at least 468,750 units of Monopar Therapeutics Inc stock.
You can see the complete history of Diane Hendricks stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Diane Hendricks's mailing address?
Diane's mailing address filed with the SEC is C/O 1000 STOKIE BLVD. STE 350, , WILMETTE, IL, .
Insiders trading at Monopar Therapeutics Inc
Over the last 5 years, insiders at Monopar Therapeutics Inc have traded over $1,830,000 worth of Monopar Therapeutics Inc stock and bought 895,199 units worth $6,154,669 . The most active insiders traders include Michael J Brown, Diane Hendricks und Pharma Llc Mazar Andrew Pau.... On average, Monopar Therapeutics Inc executives and independent directors trade stock every 15 days with the average trade being worth of $32,266. The most recent stock trade was executed by Andrew Cittadine on 30 June 2024, trading 8,952 units of MNPR stock currently worth $21,485.
What does Monopar Therapeutics Inc do?
monopar therapeutics inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the united states. it is involved in developing validive, a clonidine mucobuccal tablet that is in phase iii for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin, a topoisomerase ii-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and mnpr-101, a humanized monoclonal antibody for treating advanced solid cancers. the company has a collaboration grupo espaã±ol de investigaciã³n en sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and northstar medical radioisotopes, llc to develop radio-immuno-therapeutics targeting severe covid-19. monopar therapeutics inc. was founded in 2014 and is headquartered in wilmette, illinois.
What does Monopar Therapeutics Inc's logo look like?
Complete history of Diane Hendricks stock trades at Monopar Therapeutics Inc
Monopar Therapeutics Inc executives and stock owners
Monopar Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Dr. Chandler D. Robinson M.B.A., M.Sc., MBA, M.D., MSc,
Co-Founder, CEO, Pres & Director -
Dr. Andrew P. Mazar,
Exec. VP of R&D, Chief Scientific Officer and Director -
Kim R. Tsuchimoto CPA,
CFO, Sec. & Treasurer -
Kim R. Tsuchimoto,
CFO, Sec. & Treasurer -
Andrew J. Cittadine M.B.A.,
Chief Operating Officer -
Dr. Patrice P. Rioux M.D., Ph.D.,
Acting Chief Medical Officer -
Andrew Cittadine M.B.A.,
Chief Operating Officer -
Dr. Patrice P. Rioux,
Acting Chief Medical Officer -
Raymond Anderson,
Director -
Diane Hendricks,
-
Arthur J Klausner,
Director -
Karl Leo,
-
Pharma Llc Mazar Andrew Pau...,
Chief Scientific OfficerChief Executive Officer -
Patrice Rioux,
-
Michael J Brown,
Director -
Christopher M Starr,
Director -
Chandler Robinson,
Chief Executive Officer -
Kim R Tsuchimoto,
Chief Financial Officer -
Andrew Cittadine,
Chief Operating Officer -
Karthik Radhakrishnan,
Chief Financial Officer